In the U.S., a new formulation and an ergonomic delivery system for single doses of etanercept are now available for RA patients…
Rheumatology Drug Updates: Hip Fracture Rates After Bisphosphonate Drug Holidays, Plus More on Golimumab, Ustekinumab
Bisphosphonate Drug Holidays Drug holidays are common for patients on bisphosphonate therapy. Often, these breaks in treatment are related to known U.S. Food and Drug Administration (FDA) warnings and drug class adverse effects. Currently, data on fracture risk related to drug holidays are limited. In recent research highlighted at the 2017 ACR/ARHP Annual Meeting ,…
E6011 Safe & Well Tolerated in RA Patients
E6011, an anti-fractalkine monoclonal antibody, proved promising for the treatment of rheumatoid arthritis during a 52-week clinical trial…
Tocilizumab Monotherapy May Sustain Low Disease Activity in RA Patients
New research demonstrates that subcutaneous tocilizumab monotherapy may preserve disease control in RA patients who have discontinued methotrexate…
Pfizer’s Second Biosimilar of J&J’s Remicade Wins U.S. FDA Approval
(Reuters)—The U.S. Food and Drug Administration approved Pfizer Inc’s second biosimilar to Johnson & Johnson’s blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday. Pfizer’s Ixifi was approved for all eligible indications of Remicade, including the treatment of bowel disease Crohn’s disease and skin disorder plaque psoriasis, the drugmaker said. Biosimilars are medicines deemed…
Vitamin D-Metabolite Ratio Predicts Fracture Risk Better than 25(OH)D
NEW YORK (Reuters Health)—Vitamin D-metabolite ratio (VMR) may be a better marker of bone health than 25(OH)D (25-hydroxyvitamin D), a new study suggests. “The parameter that’s currently used to assess vitamin D status, 25(OH)D, is a flawed measure because it doesn’t consistently associate with important bone outcomes like hip fractures,” Dr. Charles Ginsberg of Veterans…
IV Saline Shortage Update
Early last month we informed you about the IV saline solution shortage that was exacerbated by Hurricane Maria’s impact on Baxter’s manufacturing facility in Puerto Rico. Since then, the ACR advocacy team has been working with the Food and Drug Administration (FDA) in its ongoing efforts to resolve the fluid shortage. Currently, the FDA has…
Drug Industry Group Sues to Stop California Drug Price Law
(Reuters)—The trade group representing U.S. drugmakers on Friday said it has a filed a lawsuit to stop California from implementing a law aimed at reining in prescription drug prices. The Pharmaceutical Research and Manufacturers of America (PhRMA), in a statement, said it filed litigation in the U.S. District Court for the Eastern District of California…
Opioid Painkiller Prescriptions May Run in Families
(Reuters Health)—When one person in a household gets prescribed opioids, the other people who live with them are more likely to get their own prescriptions for these narcotic painkillers, a U.S. study suggests. Researchers examined data on about 12.6 million people living in a household where someone was prescribed opioids and 6.4 million individuals in…
Limbrel Linked to Possible Fatal Adverse Events
The FDA is investigating serious and potentially fatal side effects associated with Limbrel, which is designed to manage metabolic processes in patients with osteoarthritis…
- « Previous Page
- 1
- …
- 57
- 58
- 59
- 60
- 61
- …
- 125
- Next Page »